QualiMed Innovative Medizinprodukte GmbH, a wholly owned subsidiary of Dublin, Ireland based Q3 Medical Devices Limited (Q3), announced that it has received CE mark approval for a dedicated percutaneous biodegradable metal alloy based stent implant for biliary applications, the UNITY-B Percutaneous Balloon Expandable Biodegradable Biliary Stent (BEBS)
| WINSEN, Germany, June 21, 2021 /PRNewswire/ -- QualiMed Innovative Medizinprodukte GmbH, a wholly owned subsidiary of Dublin, Ireland based Q3 Medical Devices Limited (Q3), announced that it has received CE mark approval for a dedicated percutaneous biodegradable metal alloy based stent implant for biliary applications, the UNITY-B Percutaneous Balloon Expandable Biodegradable Biliary Stent (BEBS). The UNITY-B Percutaneous Balloon Expandable Biodegradable Biliary Stent (BEBS) was developed for the percutaneous treatment of hepatobiliary obstruction requiring large opening drainage with the added benefit of eliminating removal procedures associated with traditional non-degradable implants. Before the recent introductions of biodegradable biliary and pancreatic drainage devices, biliary and pancreatic duct implants were made of non-degrading plastics or metals. These traditional plastic and metal implants typically require multiple procedures to place the stents, treat associated complications, and remove the implants as their removal is mandatory in most cases. The removal requirement associated with the traditional implants has the effect of doubling the total cost of care by requiring two (2) operations (1 for the device implant & 1 for the device removal) versus one (1) operation (1 for the device implant) for the biodegradable devices. Biodegradable devices have the added benefit of dissolving in the body after they have completed their work. The UNITY-B biodegradable stent is a large diameter balloon expandable biodegradable implant that is introduced percutaneously and is intended to facilitate the drainage of obstructed ducts requiring larger openings. The UNITY-B biodegradable stent is designed to replace the estimated 1 Billion Euro plus global market for non-degradable metal biliary implants. The UNITY-B biodegradable percutaneous stent was developed as an alternative to avoid the second removal procedures required with the traditional covered and uncovered metallic stents. The QualiMed percutaneous biodegradable balloon expandable implant provides an advanced treatment option to the traditional plastic and metallic implants used by Gastroenterologists, Surgeons, and Interventional Radiologists to reduce the total cost of care and complications associated with the older generation of non-biodegradable plastic and metallic implants. The UNITY-B Biodegradable Stent is designed based on the functionality of Musculoskeletal System (Bone and Muscle) where the biodegradable magnesium alloy mimics the bone and the polymer acts more like the muscle. The Skeletal (Magnesium) portion of the system serves as the main support structure. The Muscle (Polymer) helps to support movement and stability eliminating the short comings found in 1st generation biodegradable technology. In a recent safety and efficacy clinical study conducted, the UNITY-B biodegradable system showed no (0) Adverse Events and no (0) Serious Adverse Events reported as related or even possibly related to the UNITY-B study device. “The final clinical success evaluation resulted to a success rate of 94.4% which is outstanding in comparison to the ESGE 2012 guideline for traditional products, which just for stent dysfunction already reports 41%, 27% and 20% failure rate for plastic stents, uncovered SEMS (self-expandable metallic stents) and covered SEMS, respectively. Doctor Pérez-Cuadrado-Robles, an interventionalist stated, “The UNITY-B Biodegradable Stent will become a new paradigm in the management of pancreatobiliary diseases. Patients with a variety of indications, such as benign biliary strictures, biliary stones, prevention of post-sphincterotomy bleeding, biliary leaks etc. can be candidates to this technology. Indeed, this intuitive and outstanding stent can prevent second-look procedures and their procedure-related complications, resulting in a cost-effective and safe approach. Notably, the UNITY-B has major advantages in patients with a difficult access to the biliary duct (i.e., surgical anatomy). For all these reasons, this new technology should be an integral part in the management of pancreatobiliary diseases armamentarium.” “The CE mark approval of the UNITY-B Percutaneous Biodegradable implant represents yet another milestone for QualiMed and all the companies of Q3 Medical and our collective mission of Creating Value By Helping People. In these uncertain times, being able to provide total cost of care cost-saving using advanced, clinically proven products is more important than ever,” said Eric K. Mangiardi, CEO of Q3. “As we continue the development of additional biodegradable technologies to expand our portfolio for use in the gastrointestinal tract and peripheral vasculature , we are striving to shift the paradigm for treatments by reducing complications and eliminating the need for additional removal procedures or latent complications associated with the current treatment options. “This device opens a new era in biodegradable advancements that are easy to use and similar to the current technology so no additional training is needed. The technology also has the additional benefit of potentially eliminating the second procedure required for stent removal with the traditional technology and eliminating the cost of care for the patients and the insurance providers. With its reliable degradation profile, ease of use, and cost saving benefits the device will surely see utility in other applications throughout the gastrointestinal and peripheral vasculature,” said Professor of Radiology Gianpaolo Carrafiello, from the University of Milano, Milano, Italy. It is an exciting time for the company stated Eric Mangiardi, CEO of Q3 Medical as “this is only the beginning of the creative journey developing biodegradable implants for use by interventionalists and surgeons in the gastrointestinal tract as a 1st step and in the vasculature as a 2nd step. The company plans to continue its development for a variety of vascular indications including the commercialization of a specialty biodegradable implants for vascular dissections and occlusions including biodegradable covered versions of the UNITY Platform. To date Q3 Medical through its portfolio companies like QualiMed, AMG, Qsan, and QualiMed USA has 5 unique differentiated biodegradable products CE approved for treatment of a wide range of gastrointestinal indications in the hepatobiliary tract. The companies are focused on additional developments to expand the biodegradable product offering in the gastrointestinal and peripheral vascular areas. For more information, please contact Eric K. Mangiardi at 312617@email4pr.com or 353-86-782-7296. About QualiMed QualiMed was founded in 1997 as an OEM manufacturer for implantable medical devices with a focus on the development and regulatory approval of coronary stents and their respective delivery devices. Later the business was expanded to peripheral vascular and non-vascular implants. Recently QualiMed has begun developing various biodegradable technologies, drug device combination products, and micro-intervention implants as part of its diversification and competitiveness strategy. To date QualiMed has obtained CE approvals for more than 70 different products. QualiMed has developed over four Drug Eluting Stents of which it has two CE mark approvals utilizing biostable polymers and one more based on proprietary, fast-degrading, biodegradable polymer coatings entering the commercialization phase. Manufacturing is organized outside of Hamburg, Germany in the town of Winsen, where QualiMed runs two Class 10,000 Clean rooms according to EEC GMP standards. The company has production capabilities for stents, catheters, drug device combination products, and biodegradable technologies for a variety of interventional and surgical applications. About Q3 Medical Devices Ltd. Q3 Medical Devices Ltd. is an Ireland based holding company with multiple global operations in Germany, China, & the United States along with strong global partnerships and an ever growing strategic investor base. The holding and its companies are focused on Creating Value By Helping People through the development, manufacturing and distribution of its novel bioresorbable, micro invasive, localized intraluminal drug delivery, and core products platforms for interventional cardiology, peripheral vascular, and non-vascular diseases. Q3 Medical Devices Ltd. was formed by a global group of entrepreneurs, manufactures, industry doctors, and investors, focused on the development and acquisition of medical device businesses with annual revenues between 1-10 Million. The acquisitions are targeted in areas that expand the groups manufacturing base and capabilities, grow its distribution channel, and accelerate its products offering, focusing on the minimally invasive treatment of patients with cardiology, peripheral vascular and non-vascular diseases. For further information, visit http://www.q3medical.com/. Forward Looking Statements This announcement includes “forward-looking statements” which incorporate all statements other than statements of historical facts, including, without limitation, those regarding the Group’s financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group’s products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words “targets”, “believes”, “estimates”, “expects”, “aims”, “intends”, “will”, “can”, “may”, “anticipates”, “would”, “should”, “could” or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group’s control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group´s present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group’s actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Q3 Medical’s & QualiMed’s funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements are valid at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.
SOURCE QualiMed Innovative Medizinprodukte GmbH |
View original content to download multimedia:
